Search the Newsreel

ACADIA Pharmaceuticals Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ACAD) 2026-08-05

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its Q2 2026 earnings call presentation, detailing its financial results. The company reported an EPS of $0.18, beating estimates by $0.14, and revenue of $307.96 million, a 16.40% year-over-year increase, surpassing expectations by $12.44 million. This presentation provides investors …

Cementos Pacasmayo says Holcim seeks SMV extension to delay mandatory tender offer launch

Holcim has requested an exceptional extension from SMV to delay the launch of a mandatory tender offer for Cementos Pacasmayo shares. This delay is sought to push the launch deadline by up to 60 business days from the valuation firm's appointment, or five business …

Acadia Realty Trust $AKR Shares Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP increased its stake in Acadia Realty Trust (NYSE:AKR) by 3.5% in the first quarter, now owning approximately 1.4% of the company's stock. Despite missing earnings estimates in its latest quarterly report, Acadia Realty Trust maintains a "Moderate Buy" consensus rating …

RBC Capital Adjusts Price Target on ACADIA Pharmaceuticals to $37 From $36, Maintains Outperform Rating

RBC Capital has increased its price target for ACADIA Pharmaceuticals (NASDAQ: ACAD) to $37 from $36, while reiterating an Outperform rating. This adjustment follows ACADIA Pharmaceuticals' Q2 Daybue sales exceeding expectations due to Stix Formulation uptake, which supports an improved outlook for the company.

Wynn Palace Q2 Revenue Hits $653 Million, Driving Wynn Macau Parent's Profit Up 17%

Acacia Research (NASDAQ: ACTG) doubles down with 124% Q2 revenue jump and strong IP gains

Acacia Research Corporation reported a 124% increase in total revenue for Q2 2026, reaching $114.6 million, primarily driven by strong performance in Intellectual Property Operations and Benchmark Energy. Despite a $30.9 million impairment on an equity method investment, the company achieved a GAAP net …

Earnings call transcript: ACADIA tops Q2 2026 revenue forecast as shares rise

ACADIA Pharmaceuticals reported strong Q2 2026 results, with revenue reaching $308 million, surpassing analyst forecasts. The growth was primarily driven by robust sales of DAYBUE for Rett syndrome and NUPLAZID for Parkinson’s disease psychosis, leading the company to raise its 2026 DAYBUE sales guidance …

Acacia Research Reports Q2 2026 Revenue $114.6M, Adjusted Diluted EPS $0.13

Acacia Research (ACTG) reported strong Q2 2026 financial results, with total revenue reaching $114.6 million, marking a 124% year-over-year increase primarily due to higher paid-up license revenue from Intellectual Property Operations. The company also announced an Adjusted Net Income of $12.8 million and Adjusted …

Is Crédit Agricole (ENXTPA:ACA) Stock A Bargain Or Fully Priced?

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Crédit Agricole stock has delivered a strong 133.8% return over the past five years, …

Acadian Asset Management (NYSE:AAMI) Hits New 12-Month High - Should You Buy?

Vlad Anokhin has been appointed as Chief Strategy & Transformation Officer at Marriott Vacations Worldwide Corp.

Marriott Vacations Worldwide Corporation (MVW) has appointed Vlad Anokhin as its new Chief Strategy & Transformation Officer. In this role, Anokhin will lead transformation initiatives, data analytics, AI adoption, and product development for the company. He previously held leadership positions at Invited Clubs and …

CRH to buy Arcosa (NYSE: ACA) for $150 per share in cash merger

Acacia Research (ACTG) Earnings Date and Reports 2026

Is Ithaca Energy (LSE:ITH) Changing The Market View Of Oil and Gas Stocks?

ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Expected to Rise, Citizens Jmp Analyst Says

ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 1-Year High After Strong Earnings

ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Sales

Acadian Timber Q2 2026 Earnings Call Transcript

Arcosa (NYSE:ACA) Releases Earnings Results, Misses Estimates By $0.06 EPS

Arcosa (NYSE:ACA) announced its quarterly earnings, reporting $1.13 EPS, missing analyst estimates by $0.06, and revenue of $658.7 million, falling short of the $687.5 million forecast. Despite the miss, Arcosa's stock edged up 0.1% to $145.35, near its 12-month high. Analyst sentiment remains cautious …

Arcosa Stockholders Set to Vote on CRH’s $150-a-Share Acquisition Sept. 4

Cementos Pacasmayo Public History Might Be Reaching Its End (NYSE:CPAC)

Hospital Chains Stocks Q2 Earnings: Tenet Healthcare (NYSE:THC) Best of the Bunch

ACADIA Pharmaceuticals Inc (ACAD) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and ...

This article first appeared on GuruFocus. Total Revenue: $308 million in Q2 2026, representing 17% year-over-year growth on an adjusted basis. Debut (trofinetide) Net Sales: $125 million in Q2 2026, up 30% year-over-year, driven almost entirely by volume (27% from volume). Nuplazid (pimavanserin) Net …

Acadia outlines $480M-$510M 2026 DAYBUE sales outlook as remlifanserin Phase II data nears Sep-Oct

Earnings Call Insights: ACADIA Pharmaceuticals (ACAD) Q2 2026 MANAGEMENT VIEW * CEO Catherine Owen Adams said ACADIA delivered total revenues of $308 million, driven by “strong commercial execution across both DAYBUE and NUPLAZID,” and highlighted remlifanserin in Alzheimer’s disease psychosis as the lead pipeline …

Top Iron Ore Stocks to Watch: Why Is Macarthur Minerals (ASX:MIO) Worth Watching?

Q1 2025 Arcosa Inc Earnings Call Transcript

Arcosa Inc. reported a strong Q1 2025, with adjusted EBITDA growing 26% and revenue growing 12%, driven by the integration of the Stabo acquisition and strong performance in engineered structures. Despite the Stabo acquisition being dilutive to Q1 results due to its seasonality and …

Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.16 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

ACADIA Pharmaceuticals (ACAD) Stock Looks Cheap On Earnings Yet Weak On Recent Returns

ACADIA Pharmaceuticals (ACAD) stock has seen a 38.5% gain over five years but has delivered softer returns recently. Despite this, Simply Wall St's analysis suggests the stock appears relatively cheap, trading at 11.7x earnings, well below the biotech sector average, and passing multiple valuation …

Earnings Flash (ACAD) Acadia Pharmaceuticals Inc. Reports Q2 Revenue $308.0M, vs. FactSet Est of $295.5M

Acadia Pharmaceuticals Inc. (ACAD) reported its Q2 revenue at $308.0 million, surpassing the FactSet estimate of $295.5 million. The company's stock symbol is ACAD, and it operates in the Biotechnology & Medical Research sector. This positive financial performance was also accompanied by an increase …

Marriott Vacations’ New Executive Will Lead AI, Data and Products

Marriott Vacations Worldwide Corporation (NYSE: VAC) has appointed Vladimir "Vlad" Anokhin as Chief Strategy & Transformation Officer. In this role, Anokhin will be responsible for leading transformation initiatives, data analytics, artificial intelligence capabilities, and product development. His appointment reflects MVW's commitment to strengthening business …

Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results

- Second quarter DAYBUE® GAAP net sales of $125 million, up 30% year-over-year driven by strong uptake of DAYBUE STIX - Second quarter NUPLAZID® GAAP net sales of $183 million, up 10% year-over-year on a non-GAAP adjusted basis - Increased full year 2026 total …

Hotchkis & Wiley Mid-Cap Value Fund is Bullish on Marriott Vacations Worldwide (VAC)

Hotchkis & Wiley Mid-Cap Value Fund released its Q2 2026 investor letter, indicating a bullish stance on Marriott Vacations Worldwide (VAC). The fund views VAC as a quality company with a strong brand network and affluent customer base, insulating it from travel cyclicality. Despite …

Deutsche Bank Adjusts Hilton Grand Vacations Price Target to $62 From $65, Maintains Buy Rating

Deutsche Bank has adjusted its price target for Hilton Grand Vacations Inc. (HGV) to $62 from $65, while reiterating a "Buy" rating on the stock. This update reflects a slight modification in the bank's valuation outlook for the global timeshare company, which develops, markets, …

BofA Securities Maintains Acadia Realty Trust(AKR.US) With Buy Rating

BofA Securities has reiterated its Buy rating on Acadia Realty Trust (AKR.US). The article does not provide further details regarding the reasoning behind this rating.

Acadia Healthcare Company Stock Short Interest Falls to 37.33%

This article reports on the significant decrease in short interest for Acadia Healthcare Company (ACHC) stock, which fell by 37.33% in the second half of July. Despite this reduction, a substantial percentage of the company's shares are still held short, indicating continued investor sentiment …

Sei Investments Co. Has $6.35 Million Holdings in Arcosa, Inc. $ACA

Sei Investments Co. significantly increased its stake in Arcosa, Inc. by 66.3% in the first quarter, now holding shares valued at $6.35 million. Institutional investors collectively own 90.66% of Arcosa. The company's stock opened at $145.27, close to its 52-week high, and maintains a …